Measurable residual disease as predictor of post–day +100 relapses after allografting in adult AML
Abstract: Measurable residual disease (MRD) by multiparametric flow cytometry (MFC) before allogeneic hematopoietic cell transplantation (HCT) identifies patients at high risk of acute myeloid leukemia (AML) relapse, often occurring early after allografting. To examine the role of MFC MRD testing to...
Saved in:
Main Authors: | Naveed Ali, Megan Othus, Eduardo Rodríguez-Arbolí, Corentin Orvain, Filippo Milano, Brenda M. Sandmaier, Chris Davis, Ryan S. Basom, Frederick R. Appelbaum, Roland B. Walter |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | Blood Advances |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952924005998 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Does the regional use of intensive chemotherapy impact the outcome of adults with AML?
by: Corentin Orvain
Published: (2024-12-01) -
Granulocytic Sarcoma of the Uterus: A Rare Presentation of Extramedullary Relapse of AML and Importance of MRI
by: Murat Ucar, et al.
Published: (2014-01-01) -
Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML
by: Julia M. Unglaub, et al.
Published: (2025-01-01) -
Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial
by: Ruihao Huang, et al.
Published: (2025-01-01) -
100 days on: the primary care response to COVID-19 in Singapore
by: Yiyang Liow, et al.
Published: (2022-09-01)